Outset Medical Earnings Call Highlights Margin Turnaround

Outset Medical, Inc. ((OM)) has held its Q4 earnings call. Read on for the main highlights of the call.

Outset Medical’s latest earnings call painted a cautiously optimistic picture, with clear gains in margins, cost control and balance-sheet strength offset by ongoing net losses and moderate top-line growth. Management stressed that improved unit economics, a cyber-hardened next‑gen Tablo, and strong customer satisfaction are extending the cash runway even as sales cycles and product timing remain headwinds.

Full-Year Revenue Growth

Outset closed fiscal 2025 with revenue of $119.5 million, a 5% increase from 2024 that underscores steady but not explosive growth. Management signaled confidence in sustaining that trajectory, projecting 2026 revenue between $125 million and $130 million, implying a further 5%–9% expansion.

Quarterly and Product Details

Fourth-quarter revenue reached $28.9 million, including $19.9 million of product revenue and $13.5 million from consumables. Console sales rose 11% to $6.4 million, while consumables rebounded sequentially, climbing about 11% from Q3, highlighting improving utilization of the installed base.

Significant Gross Margin Expansion

Non‑GAAP gross margin expanded roughly 500 basis points year over year to 42.9% in Q4, and full‑year non‑GAAP gross margin improved 400 basis points to 39.6%. Excluding manufacturing under‑absorption, full‑year gross margin reached 41.1%, and product gross margin topped 50% for the first time at 50.7%, up 640 basis points.

Improved Profitability Trajectory and Expense Discipline

Non‑GAAP operating expenses fell about 4% in Q4 to $25.7 million and declined 19% for the full year to $97.8 million, reflecting tighter cost control. That discipline helped narrow the non‑GAAP net loss to $65.4 million for 2025, a 31% improvement, with Q4’s non‑GAAP net loss down 22% year over year to $15 million.

Stronger Cash Position and Reduced Cash Burn

The company ended Q4 with $173 million in cash, cash equivalents and investments, having used roughly $9 million in the quarter. Full‑year cash use dropped sharply to $46 million from $116 million previously, and management expects even lower cash consumption in 2026, asserting that current liquidity should be enough to reach profitability.

FDA Clearance and Product Leadership

Outset secured FDA clearance for its next‑generation Tablo, the first dialysis system cleared under the agency’s 2025 cybersecurity requirements, reinforcing its positioning as a technology leader. The new system is slated for a late‑Q2 launch, including upgrades for the installed base, and Tablo now operates at about 1,000 acute care sites with more than 3 million cumulative treatments delivered.

Clinical and Customer Momentum

Management highlighted growing clinical evidence that Tablo can lower infection rates and reduce hospital length of stay, strengthening the economic case for adoption. Customer satisfaction remains above 95%, and the company is expanding master sales and service agreements, including a recent contract covering more than 100 facilities.

Q4 Product Revenue Below Prior-Year Quarter

Despite sequential strength, Q4 product revenue of $19.9 million was below the prior year’s $21 million, reflecting year‑on‑year softness. Management attributed part of the decline to the timing of consumable orders, which can create quarterly volatility in reported numbers even as underlying demand trends remain positive.

Manufacturing Under-Absorption Headwind

Manufacturing under‑absorption trimmed non‑GAAP gross margin by about 130 basis points in Q4 and roughly 150 basis points for the full year, partially masking underlying margin gains. The company expects this headwind to ease in 2026 as volumes and factory utilization improve, providing an additional tailwind to gross margin.

Sustained Net Loss and Cash Use

Even with progress on margins and expenses, Outset still posted a full‑year non‑GAAP net loss of $65.4 million and used $46 million of cash in 2025. Management cautioned that Q1 2026 will be the highest cash‑use quarter, driven by inventory builds and manufacturing investments needed to support future growth.

Moderate Near-Term Growth Outlook

The near‑term growth profile remains measured, with 2026 revenue expected to rise just 5%–9% and non‑GAAP gross margin targeted in the low‑to‑mid‑40% range. Q1 revenue is projected to be roughly flat with Q4 2025 before improving later in the year, signaling a gradual rather than rapid acceleration.

Sales Cycle Length and Timing Uncertainty

Large enterprise deals often take 9–12 months or more to close, with some stretching toward 18 months, which can delay revenue recognition. The company noted that order timing variability, particularly in consumables, continues to cause year‑on‑year fluctuations and complicates short‑term forecasting despite better internal visibility.

Next-Gen Tablo Pricing and Margin Transition

Management did not reveal average selling prices for the next‑generation Tablo and acknowledged that launch dynamics could modestly pressure gross margins in the near term. A higher mix of console sales versus consumables could weigh on margins during the transition, though the impact is expected to be mild and temporary.

Guidance and Forward-Looking Outlook

For 2026, Outset guided revenue to $125 million–$130 million with non‑GAAP gross margin in the low‑to‑mid‑40% range, expecting the manufacturing under‑absorption drag from 2025 to fade. Operating expenses are projected to grow at roughly half the pace of sales, cash use should fall below 2025’s $46 million, and the next‑gen Tablo is planned for commercial launch in late Q2.

Outset’s earnings call depicted a company in transition from heavy investment toward a more sustainable, margin‑driven model, even as net losses and moderate growth temper the story. For investors, the key watchpoints in 2026 will be execution on the next‑gen Tablo launch, continued gross margin expansion, and proof that the current cash balance can indeed carry the business to profitability.